Targeting MicroRNAs in Prevention and Treatment of Neurodegenerative Disorders

Drug Development Research

Volumn 76, Issue 7, 2015, Pages 397-418

  Gupta, Smriti ^a   Verma, Savita ^a   Mantri, Shrikant ^b   Berman, Nancy E ^c   Sandhir, Rajat ^a  

^a PANJAB UNIVERSITY   (India)

^b NATIONAL AGRI FOOD BIOTECHNOLOGY INSTITUTE   (India)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

brain; epigenetics; miRNAs; neurodegeneration; noncoding RNAs

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; MICRORNA; MICRORNA 101; MICRORNA 106A; MICRORNA 106AB; MICRORNA 124; MICRORNA 125B1; MICRORNA 125B2; MICRORNA 146A; MICRORNA 147; MICRORNA 150; MICRORNA 153; MICRORNA 17; MICRORNA 19B 1; MICRORNA 200A; MICRORNA 200C; MICRORNA 20A; MICRORNA 21; MICRORNA 22; MICRORNA 26A 2; MICRORNA 29C; MICRORNA 323 3P; MICRORNA 34B; MICRORNA 520C; MICRORNA 644; MICRORNA 655; MICRORNA 7; PRESENILIN; TAU PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ALZHEIMER DISEASE; BRAIN INFARCTION; DEGENERATIVE DISEASE; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUNTINGTON CHOREA; LEWY BODY; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; PARKINSON DISEASE; PRION DISEASE; REVIEW; TRANSCRIPTION REGULATION; UPREGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MOLECULARLY TARGETED THERAPY; NEURODEGENERATIVE DISEASES;

GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES;

EID: 84945440143     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21277     Document Type: Review

References (134)

1. Absalon S, Kochanek DM, Raghavan V, Krichevsky AM., 2013. MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci 33: 14645-14659.
2. Alexandrov PN, Dua P, Lukiw WJ., 2014. Up-regulation of miRNA-146a in progressive, age-related inflammatory neurodegenerative disorders of the human CNS. Front Neurol 5: 181.
3. Alvarez-Erviti L, Seow Y, Schapira AH, Rodriguez-Oroz MC, Obeso JA, Cooper JM., 2013. Influence of microRNA deregulation on chaperone-mediated autophagy and alpha-synuclein pathology in Parkinson's disease. Cell Death Dis 4: e545.
4. Ambros V., 2004. The functions of animal microRNAs. Nature 431: 350-355.
5. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C,. 1991. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337: 1521-1526. DOI: 0140-6736(91)93206-O
6. Bartel DP., 2009. MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
7. Ben Haim L, Ceyzeriat K, Carrillo-de Sauvage MA, Aubry F, Auregan G, Guillermier M, Ruiz M, Petit F, Houitte D, Faivre E, et al., 2015. The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer's and Huntington's diseases. J Neurosci 35: 2817-2829.
8. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, Thurman RE, et al., 2007. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447: 799-816.
9. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, et al., 2008. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277.
10. Braak H, Braak E., 1996. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 165: 3-12.
11. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al., 2002. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529.
12. Cao J, Luo Z, Cheng Q, Xu Q, Zhang Y, Wang F, Wu Y, Song X., 2015. Three-dimensional regulation of transcription. Protein Cell 6: 241-253.
13. Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S., 2001. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 24: 182-188.
14. Cepeda C, Murphy KP, Parent M, Levine MS., 2014. The role of dopamine in Huntington's disease. Prog Brain Res 211: 235-254.
15. Chan JA, Krichevsky AM, Kosik KS., 2005. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033.
16. Chen Y, Liu W, Chao T, Zhang Y, Yan X, Gong Y, Qiang B, Yuan J, Sun M, Peng X., 2008. MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett 272: 197-205.
17. Cho HJ, Liu G, Jin SM, Parisiadou L, Xie C, Yu J, Sun L, Ma B, Ding J, Vancraenenbroeck R, et al., 2013. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet 22: 608-620.
18. Cochella L, Hobert O., 2012. Diverse functions of microRNAs in nervous system development. Curr Top Dev Biol 99: 115-143.
19. Coppede F., 2012. Genetics and epigenetics of Parkinson's disease. ScientificWorldJournal 2012: 489830.
20. Cui JG, Kuroda H, Chandrasekharan NV, Pelaez RP, Simmons DL, Bazan NG, Lukiw WJ., 2004. Cyclooxygenase-3 gene expression in Alzheimer hippocampus and in stressed human neural cells. Neurochem Res 29: 1731-1737.
21. Cui JG, Li YY, Zhao Y, Bhattacharjee S, Lukiw WJ., 2010. Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease. J Biol Chem 285: 38951-38960.
22. Cullen BR., 2004. Transcription and processing of human microRNA precursors. Mol Cell 16: 861-865.
23. De Strooper B, Iwatsubo T, Wolfe MS., 2012. Presenilins and gamma-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb Perspect Med 2: a006304.
24. Donev R, Kolev M, Millet B, Thome J., 2009. Neuronal death in Alzheimer's disease and therapeutic opportunities. J Cell Mol Med 13: 4329-4348.
25. Doxakis E., 2010. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem 285: 12726-12734.
26. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ., 2008. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7: 759-764.
27. Fallon L, Belanger CM, Corera AT, Kontogiannea M, Regan-Klapisz E, Moreau F, Voortman J, Haber M, Rouleau G, Thorarinsdottir T, et al., 2006. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol 8: 834-842.
28. Fiore R, Khudayberdiev S, Saba R, Schratt G., 2011. MicroRNA function in the nervous system. Prog Mol Biol Transl Sci 102: 47-100.
29. Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schule B, Langston JW, Middleton FA, Ross OA, Hulihan M, et al., 2007. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68: 916-922.
30. Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, Koli P, Sen E, Basu A., 2007. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 55: 483-496.
31. Giese A, Brown DR, Groschup MH, Feldmann C, Haist I, Kretzschmar HA., 1998. Role of microglia in neuronal cell death in prion disease. Brain Pathol 8: 449-457.
32. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, et al., 2005. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365: 415-416.
33. Golde TE, Estus S, Usiak M, Younkin LH, Younkin SG., 1990. Expression of beta amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer's disease using PCR. Neuron 4: 253-267.
34. Goodall EF, Heath PR, Bandmann O, Kirby J, Shaw PJ., 2013. Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. Front Cell Neurosci 7: 178.
35. Griffiths-Jones S., 2004. The microRNA Registry. Nucleic Acids Res 32: D109-D111.
36. Griffiths-Jones S., 2006. miRBase: the microRNA sequence database. Methods Mol Biol 342: 129-138.
37. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ., 2006. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140-D144.
38. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ., 2008. miRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154-D158.
39. Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, Scherr M, Castermans K, Malvaux L, Lambert V, Thiry M, et al., 2013. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 123: 2143-2154.
40. Hammond SM., 2005. Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett 579: 5822-5829.
41. Hannun YA, Obeid LM., 2008. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139-150.
42. Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C., 2009. The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev 19: 254-265.
43. Hawkins PG, Morris KV., 2008. RNA and transcriptional modulation of gene expression. Cell Cycle 7: 602-607.
44. He L, Hannon GJ., 2004. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531.
45. Hebert SS, De Strooper B., 2009. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci 32: 199-206.
46. Hebert SS, Papadopoulou AS, Smith P, Galas MC, Planel E, Silahtaroglu AN, Sergeant N, Buee L, De Strooper B., 2010. Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet 19: 3959-3969.
47. Hock J, Meister G., 2008. The Argonaute protein family. Genome Biol 9: 210.
48. Hu YK, Wang X, Li L, Du YH, Ye HT, Li CY., 2013. MicroRNA-98 induces an Alzheimer's disease-like disturbance by targeting insulin-like growth factor 1. Neurosci Bull 29: 745-751.
49. Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, Dalby CM, Robinson K, Stack C, Latimer PA, et al., 2012. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 110: 71-81.
50. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T, et al., 2009. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 23: 1327-1337.
51. Huttenhofer A, Schattner P, Polacek N., 2005. Non-coding RNAs: hope or hype? Trends Genet 21: 289-297.
52. Itoh N, Ohta H., 2013. Roles of FGF20 in dopaminergic neurons and Parkinson's disease. Front Mol Neurosci 6: 15.
53. Jacobsen JS, Blume AJ, Vitek MP., 1991. Quantitative measurement of alternatively spliced amyloid precursor protein mRNA expression in Alzheimer's disease and normal brain by S1 nuclease protection analysis. Neurobiol Aging 12: 585-592.
54. Jayadev S, Case A, Alajajian B, Eastman AJ, Moller T, Garden GA., 2013. Presenilin 2 influences miR146 level and activity in microglia. J Neurochem 127: 592-599.
55. Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, Bird TD., 2010. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 133 (Pt 4): 1143-1154.
56. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, et al., 2007. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67: 7713-7722.
57. Johnson R, Buckley NJ., 2009. Gene dysregulation in Huntington's disease: REST, microRNAs and beyond. Neuromol Med 11: 183-199.
58. Johnson R, Zuccato C, Belyaev ND, Guest DJ, Cattaneo E, Buckley NJ., 2008. A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol Dis 29: 438-445.
59. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ., 2005. RAS is regulated by the let-7 microRNA family. Cell 120: 635-647.
60. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, et al., 2008. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572.
61. Khoo SK, Petillo D, Kang UJ, Resau JH, Berryhill B, Linder J, Forsgren L, Neuman LA, Tan AC., 2012. Plasma-based circulating MicroRNA biomarkers for Parkinson's disease. J Parkinsons Dis 2: 321-331.
62. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, Abeliovich A., 2007. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317: 1220-1224.
63. Kosik KS., 2006. The neuronal microRNA system. Nat Rev Neurosci 7: 911-920.
64. Kosik KS, Krichevsky AM., 2005. The elegance of the microRNAs: a neuronal perspective. Neuron 47: 779-782.
65. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T., 2001. Identification of novel genes coding for small expressed RNAs. Science 294: 853-858.
66. Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, Dhanasekaran SM, Chinnaiyan AM, Athey BD., 2009. New class of microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction sites. Genome Res 19: 1175-1183.
67. Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT, Jr., Kosik KS., 1998. A detergent-insoluble membrane compartment contains a beta in vivo. Nat Med 4: 730-734.
68. Lee VM, Goedert M, Trojanowski JQ., 2001. Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121-1159.
69. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN., 2004. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23: 4051-4060.
70. Liu B, Hong JS., 2003. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304: 1-7.
71. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al, 2011. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215.
72. Liu R, Yi B, Wei S, Yang WH, Hart KM, Chauhan P, Zhang W, Mao X, Liu X, Liu CG, et al., 2015. FOXP3-miR-146-NF-kappaB axis and therapy for precancerous lesions in prostate. Cancer Res 75: 1714-1724.
73. Liu W, Mao SY, Zhu WY., 2007. Impact of tiny miRNAs on cancers. World J Gastroenterol 13: 497-502.
74. Long JM, Ray B, Lahiri DK., 2012. MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem 287: 31298-31310.
75. Lukiw WJ, Dua P, Pogue AI, Eicken C, Hill JM., 2011. Upregulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome. J Toxicol Environ Health A 74: 1460-1468.
76. Lukiw WJ, Percy ME, Kruck TP., 2005. Nanomolar aluminum induces pro-inflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem 99: 1895-1898.
77. Lukiw WJ, Zhao Y, Cui JG., 2008. An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 283: 31315-31322.
78. Maciotta S, Meregalli M, Torrente Y., 2013. The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci 7: 265.
79. Mei Y, Bian C, Li J, Du Z, Zhou H, Yang Z, Zhao RC., 2013. miR-21 modulates the ERK-MAPK signaling pathway by regulating SPRY2 expression during human mesenchymal stem cell differentiation. J Cell Biochem 114: 1374-1384.
80. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T., 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658.
81. Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, McLendon C, Carter DM, Zhu PP, Stadler J, Chandran J, et al, 2003. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem 278: 36588-36595.
82. Minones-Moyano E, Porta S, Escaramis G, Rabionet R, Iraola S, Kagerbauer B, Espinosa-Parrilla Y, Ferrer I, Estivill X, Marti E., 2011. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 20: 3067-3078.
83. Miska EA, Alvarez-Saavedra E, Townsend M, Yoshii A, Sestan N, Rakic P, Constantine-Paton M, Horvitz HR., 2004. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol 5: R68.
84. Nalluri JJ, Kamapantula BK, Barh D, Jain N, Bhattacharya A, de Almeida S, Juca Ramos R, Silva A, Azevedo V, Ghosh P., 2015. DISMIRA: prioritization of disease candidates in miRNA-disease associations based on maximum weighted matching inference model and motif-based analysis. BMC Genomics 16 (Suppl 5): S12.
85. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, et al, 1999. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 274: 9843-9846.
86. Nelson PT, Baldwin DA, Kloosterman WP, Kauppinen S, Plasterk RH, Mourelatos Z., 2006. RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA 12: 187-191.
87. Neve RL, Rogers J, Higgins GA., 1990. The Alzheimer amyloid precursor-related transcript lacking the beta/A4 sequence is specifically increased in Alzheimer's disease brain. Neuron 5: 329-338.
88. Nunez-Iglesias J, Liu CC, Morgan TE, Finch CE, Zhou XJ., 2010. Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation. PLoS One 5: e8898.
89. O'Brien RJ, Wong PC., 2011. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 34: 185-204.
90. Papagiannakopoulos T, Shapiro A, Kosik KS., 2008. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68: 8164-8172.
91. Pearson H., 2006. Genetics: what is a gene? Nature 441: 398-401.
92. Pogue AI, Li YY, Cui JG, Zhao Y, Kruck TP, Percy ME, Tarr MA, Lukiw WJ., 2009. Characterization of an NF-kappaB-regulated, miRNA-146a-mediated down-regulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells. J Inorg Biochem 103: 1591-1595.
93. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffer AA, et al., 1996. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274: 1197-1199.
94. Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, Sadek HA,. 2011. Transient regenerative potential of the neonatal mouse heart. Science 331: 1078-1080. DOI: 331/6020/1078
95. Prusiner SB., 1998. Prions. Proc Natl Acad Sci USA 95: 13363-13383.
96. Rajewsky N., 2006. L(ou)sy miRNA targets? Nat Struct Mol Biol 13: 754-755.
97. Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L., 1995. Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem 270: 28257-28267.
98. Saba R, Goodman CD, Huzarewich RL, Robertson C, Booth SA., 2008. A miRNA signature of prion induced neurodegeneration. PLoS One 3: e3652.
99. Sandhir R, Gregory E, Berman NE., 2014. Differential response of miRNA-21 and its targets after traumatic brain injury in aging mice. Neurochem Int 78: 117-121.
100. Savas JN, Makusky A, Ottosen S, Baillat D, Then F, Krainc D, Shiekhattar R, Markey SP, Tanese N., 2008. Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc Natl Acad Sci USA 105: 10820-10825.
101. Sayed D, Abdellatif M., 2011. MicroRNAs in development and disease. Physiol Rev 91: 827-887.
102. Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, Bates GP, Lehrach H, Wanker EE., 1999. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci USA 96: 4604-4609.
103. Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R., 2010. Gliomas in adults. Dtsch Arztebl Int 107: 799-807; quiz 808.
104. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT., 2011. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1: a006189.
105. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, et al., 2000. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25: 302-305.
106. Singh RB, Mengi SA, Xu YJ, Arneja AS, Dhalla NS., 2002. Pathogenesis of atherosclerosis: a multifactorial process. Exp Clin Cardiol 7: 40-53.
107. Singh SK., 2007. miRNAs: from neurogeneration to neurodegeneration. Pharmacogenomics 8: 971-978.
108. Smith P, Al Hashimi A, Girard J, Delay C, Hebert SS., 2011. In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs. J Neurochem 116: 240-247.
109. Sotiriou S, Gibney G, Baxevanis AD, Nussbaum RL., 2009. A single nucleotide polymorphism in the 3′UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease. Neurosci Lett 461: 196-201.
110. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M., 1998. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251: 205-208.
111. Strickland IT, Richards L, Holmes FE, Wynick D, Uney JB, Wong LF., 2011. Axotomy-induced miR-21 promotes axon growth in adult dorsal root ganglion neurons. PLoS One 6: e23423.
112. Switonski PM, Szlachcic WJ, Gabka A, Krzyzosiak WJ, Figiel M., 2012. Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. Mol Neurobiol 46: 430-466.
113. Taganov KD, Boldin MP, Chang KJ, Baltimore D., 2006. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103: 12481-12486.
114. Tan Y, Zhang B, Wu T, Skogerbo G, Zhu X, Guo X, He S, Chen R., 2009. Transcriptional inhibiton of Hoxd4 expression by miRNA-10a in human breast cancer cells. BMC Mol Biol 10: 12.
115. Tang K, Wang C, Shen C, Sheng S, Ravid R, Jing N., 2003. Identification of a novel alternative splicing isoform of human amyloid precursor protein gene, APP639. Eur J Neurosci 18: 102-108.
116. Tanzi R, Gaston S, Bush A, Romano D, Pettingell W, Peppercorn J, Paradis M, Gurubhagavatula S, Jenkins B, Wasco W., 1993. Genetic heterogeneity of gene defects responsible for familial Alzheimer disease. Genetica 91: 255-263.
117. Thorsen SB, Obad S, Jensen NF, Stenvang J, Kauppinen S., 2012. The therapeutic potential of microRNAs in cancer. Cancer J 18: 275-284.
118. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, et al., 2004. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304: 1158-1160.
119. Van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN., 2007. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316: 575-579.
120. Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, Sisodia SS, Thinakaran G., 2005. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem 280: 25892-25900.
121. Vilardo E, Barbato C, Ciotti M, Cogoni C, Ruberti F., 2010. MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons. J Biol Chem 285: 18344-18351.
122. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB,. 2008 Alternative isoform regulation in human tissue transcriptomes. Nature 456: 470-476
123. Wang LL, Huang Y, Wang G, Chen SD., 2012. The potential role of microRNA-146 in Alzheimer's disease: biomarker or therapeutic target? Med Hypotheses 78: 398-401.
124. Wang QT, Piotrowska K, Ciemerych MA, Milenkovic L, Scott MP, Davis RW, Zernicka-Goetz M,. 2004. A genome-wide study of gene activity reveals developmental signaling pathways in the preimplantation mouse embryo. Dev Cell 6: 133-144. DOI: S1534580703004040
125. Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ, Jr., Lazo JS, Wang Z, Zhang L, Yu J., 2009. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 69: 8157-8165.
126. Wang WX, Huang Q, Hu Y, Stromberg AJ, Nelson PT., 2011. Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol 121: 193-205.
127. Weng H, Shen C, Hirokawa G, Ji X, Takahashi R, Shimada K, Kishimoto C, Iwai N., 2011. Plasma miR-124 as a biomarker for cerebral infarction. Biomed Res 32: 135-141.
128. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG., 2010. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70: 5923-5930.
129. Winslow AR, Rubinsztein DC., 2011. The Parkinson disease protein alpha-synuclein inhibits autophagy. Autophagy 7: 429-431.
130. Yang JH, Li JH, Jiang S, Zhou H, Qu LH., 2013. ChIPBase: a database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data. Nucleic Acids Res 41: D177-D187.
131. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH., 2010. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 411: 846-852.
132. Zhang L, Dong LY, Li YJ, Hong Z, Wei WS., 2012. miR-21 represses FasL in microglia and protects against microglia-mediated neuronal cell death following hypoxia/ischemia. Glia 60: 1888-1895.
133. Zhang YW, Thompson R, Zhang H, Xu H., 2011. APP processing in Alzheimer's disease. Mol Brain 4: 3.
134. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T, et al., 2003. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35: 76-83.